K-CAB Marks HK inno.N’s Shift From Domestic Growth to Global Expansion

A review of HK inno.N’s fourth-quarter earnings release, posted on Feb. 10, shows that three of its eight pages are devoted to K-CAB—underscoring the drug’s outsized importance to the company after more than a decade of development and sustained investment.

K-CAB has emerged as the company’s core growth engine, lifting HK inno.N into the $700 million revenue tier while delivering both sales growth and royalty income. At the same time, the healthcare (H&B) business—previously weighed down by product recalls—has entered a phase of normalization, supported by co-promotion products that reinforced overall performance throughout the year.

HK inno.N reported 2025 revenue of $727 million, up 18.5% from $614 million a year earlier. Operating profit rose 25.7% to $75.9 million, pushing the operating margin into double digits at 10.4%. Net profit increased 22.9% year on year to $51.8 million.

Management attributed the growth to stable ETC product sales and an expanded co-promotion portfolio. In infusion therapies, sales reached $24.3 million, up 13.5% year on year, driven by higher-margin nutritional infusions such as TPN.

The company also scaled up revenue through successive co-promotion agreements with AstraZeneca, Roche, and Pfizer, adding a dapagliflozin combination, a COVID-19 vaccine, and a macular degeneration therapy, respectively. External conditions further supported results, as easing medical strikes led to increased prescriptions for Roche’s Avastin and higher demand for infusion products.

Still, the primary driver behind HK inno.N’s entry into the “$700 million club” was its potassium-competitive acid blocker K-CAB (tegoprazan). While Avastin prescriptions grew at a faster rate, K-CAB delivered the largest absolute contribution.

Fourth-quarter revenue totaled $185 million, up 27.4% year on year, with K-CAB contributing $36 million—about 20% of the total. On a full-year basis, K-CAB recorded prescription sales of $149 million, closely tracking the company’s overall growth trajectory.

Market data cited from UBIST further highlight K-CAB’s position. With the digestive ulcer drug market valued at $1.01 billion in 2025, roughly 15% of patients in the segment were treated with K-CAB.

A notable change in the fourth-quarter IR materials is the inclusion of “K-CAB exports: $3.5 million.” While still modest, exports have expanded from two countries to 18, signaling tangible progress in global commercialization.

This shift is reflected in disclosure updates. Contracts now cover 55 countries, with launches in 19 markets, up from 53 and 18, respectively, in the third quarter. Regulatory approvals have also been completed in Paraguay, Ecuador, and Russia.

The United States remains the most closely watched market. Under a licensing deal worth approximately $438 million with Sebela Pharmaceuticals, K-CAB’s U.S. status is now listed as “NDA submitted,” indicating that the New Drug Application filing has been completed.

Estimates place the U.S. peptic ulcer drug market at just under $2.74 billion. Phathom Pharmaceuticals’ P-CAB Voquezna—based on vonoprazan, widely known as Takeda’s Takecab—generated $55.3 million in sales in its first year on the market in 2024. The U.S. accounts for roughly 40% of the global peptic ulcer market, leaving significant room for further P-CAB penetration.

In parallel, HK inno.N is preparing for Japan—the world’s most established P-CAB market—by becoming the largest shareholder of RaQualia Pharma, the originator of the K-CAB compound. This positions the company for entry into both the largest market and the market with the deepest P-CAB adoption.

The IR materials also point to a clear turnaround in the H&B business. As recently as the third quarter, the segment posted an operating loss of $3.2 million due to recall-related impacts. While fourth-quarter revenue declined 8.9% year on year to $14.5 million, operating profit rebounded to $3.56 million, marking a decisive recovery.

Sales of the flagship hangover remedy Condition fell 10.4% year on year to $9.92 million, but improved sharply from $7.12 million in the third quarter. The rebound was supported by an expanded product lineup—including Condition Sparkling—along with aggressive marketing. Distribution of other beverage products also stabilized, with convenience-store shipments recovering to about 90% of year-ago levels.

Since 2020, K-CAB has remained HK inno.N’s central growth engine. Its accelerating global expansion—where investment has been most concentrated—signals that the company’s ambitions now extend well beyond the $700 million milestone, marking a strategic shift that warrants continued attention.